Evobrutinib

CAS No. 1415823-73-2

Evobrutinib( M2951 | MSC2364447C | MSC 2364447 )

Catalog No. M11730 CAS No. 1415823-73-2

A potent, highly selective BTK inhibitor for the treatment of various autoimmune disorders.Rheumatoid ArthritisPhase 2 Clinical

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 60 In Stock
5MG 85 In Stock
10MG 141 In Stock
25MG 284 In Stock
50MG 426 In Stock
100MG 624 In Stock
500MG 1314 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Evobrutinib
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, highly selective BTK inhibitor for the treatment of various autoimmune disorders.Rheumatoid ArthritisPhase 2 Clinical
  • Description
    A potent, highly selective BTK inhibitor for the treatment of various autoimmune disorders.Rheumatoid Arthritis Phase 2 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    M2951 | MSC2364447C | MSC 2364447
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK
  • Research Area
    Inflammation/Immunology
  • Indication
    Rheumatoid Arthritis

Chemical Information

  • CAS Number
    1415823-73-2
  • Formula Weight
    429.51418
  • Molecular Formula
    C25H27N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 6.4 mg/mL (Need ultrasonic)
  • SMILES
    C=CC(N1CCC(CNC2=NC=NC(N)=C2C3=CC=C(OC4=CC=CC=C4)C=C3)CC1)=O
  • Chemical Name
    2-Propen-1-one, 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Patent US20140162983 example 0174.
molnova catalog
related products
  • Btk inhibitor 2

    Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).

  • Vecabrutinib

    Vecabrutinib (SNS-062) is a potent, reversible, non-covalent BTK inhibitor with IC50 of 2.9 and 4.4 nM for WT BTK and C481S BTK, respectively;

  • Acalabrutinib

    A novel, irreversible, covalent second-generation BTK inhibitor with IC50 of 3 nM.